Hui Tian, PhD
Dr. Hui Tian joined The Column Group in 2022 as a Venture Partner. Previously he was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span of 14 years, he led the discovery and advancement of more than a dozen clinical candidates. Prior to NGM, he was a Scientific Director at Amgen and Tularik leading discovery research in the areas of metabolic disorders and orphan G protein-coupled receptors. Dr. Tian received a Ph.D. in Molecular and Cellular Biology at the University of Texas Southwestern Medical Center and did his post-doctoral training at Harvard University.
Board of Directors: Kimia